Jones Trading Begins Coverage on Dyne Therapeutics (NASDAQ:DYN)

Equities researchers at Jones Trading began coverage on shares of Dyne Therapeutics (NASDAQ:DYN - Get Free Report) in a note issued to investors on Thursday,Benzinga reports. The firm set a "buy" rating and a $30.00 price target on the stock. Jones Trading's price objective indicates a potential upside of 187.91% from the stock's previous close.

DYN has been the topic of a number of other reports. Chardan Capital restated a "buy" rating and set a $50.00 price target on shares of Dyne Therapeutics in a research note on Tuesday, June 17th. BMO Capital Markets initiated coverage on Dyne Therapeutics in a research note on Wednesday, March 12th. They issued an "outperform" rating and a $50.00 price target on the stock. Sanford C. Bernstein assumed coverage on shares of Dyne Therapeutics in a research report on Tuesday. They set a "market perform" rating and a $13.00 price objective for the company. Raymond James Financial assumed coverage on Dyne Therapeutics in a research note on Wednesday, June 11th. They set an "outperform" rating and a $37.00 price target on the stock. Finally, Guggenheim reaffirmed a "buy" rating and issued a $50.00 target price on shares of Dyne Therapeutics in a report on Wednesday, June 18th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $41.13.

Dyne Therapeutics Trading Down 2.0%

Shares of DYN stock opened at $10.42 on Thursday. Dyne Therapeutics has a twelve month low of $6.36 and a twelve month high of $47.45. The stock has a market cap of $1.18 billion, a P/E ratio of -2.90 and a beta of 1.16. The stock has a 50 day moving average of $11.76 and a 200 day moving average of $14.20.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.17). On average, research analysts predict that Dyne Therapeutics will post -3.44 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Dyne Therapeutics

A number of institutional investors have recently bought and sold shares of DYN. Bank of New York Mellon Corp grew its stake in Dyne Therapeutics by 0.3% in the fourth quarter. Bank of New York Mellon Corp now owns 234,798 shares of the company's stock valued at $5,532,000 after purchasing an additional 698 shares in the last quarter. Summit Investment Advisors Inc. lifted its holdings in shares of Dyne Therapeutics by 9.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company's stock worth $203,000 after buying an additional 721 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of Dyne Therapeutics by 5.2% during the first quarter. China Universal Asset Management Co. Ltd. now owns 22,690 shares of the company's stock valued at $237,000 after buying an additional 1,115 shares during the last quarter. E Fund Management Co. Ltd. lifted its position in shares of Dyne Therapeutics by 11.8% in the 4th quarter. E Fund Management Co. Ltd. now owns 11,848 shares of the company's stock worth $279,000 after acquiring an additional 1,249 shares during the period. Finally, Arizona State Retirement System raised its stake in shares of Dyne Therapeutics by 9.2% in the 1st quarter. Arizona State Retirement System now owns 17,501 shares of the company's stock valued at $183,000 after buying an additional 1,481 shares in the last quarter. Hedge funds and other institutional investors own 96.68% of the company's stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.